Bing Xu

The paper identifies NALHP/S6, a heparin derivative, as a glycan-based modulator that restores mucosal barrier function in ulcerative colitis by promoting a repair-secretory epithelial state.

This paper develops an oral nanotherapeutic, OPNs@LMWH, that targets intestinal integrins and regulates redox homeostasis to treat ulcerative colitis, showing improved therapeutic efficacy and immune uptake.

The paper identifies a novel tetrapeptide VAMP from hemp seed protein hydrolysates that inhibits DPP-IV and increases Akkermansia muciniphila abundance, improving glucose homeostasis in obese mice.